$UNH

Conway Patrick Hugh sold $205K of UNH

Conway Patrick Hugh (Chief Executive Officer, Optum) sold 500 shares of UNITEDHEALTH GROUP INC (UNH) at $410.00 ($0.20M total) on 2026-08-05.

Original reporting
SEC EDGAR · Conway Patrick Hugh
Published Aug 7, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$UNH
Neutral
medium confidence
Mentioned
$UNH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UNHNeutralLow
01

Why it matters

The only new information is the disclosed sale: 500 shares at $410 for about $205,000, with holdings after the transaction of 16,497 shares.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no accompanying guidance, earnings, regulatory, or deal catalyst in the text.

03

What to watch

The article does not state whether the sale was part of a broader pattern, whether other insiders sold/bought, or whether there were concurrent compensation events that could explain the transaction.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-07, transaction dated 2026-08-05

Background

The filing is an SEC Form 4 insider transaction for UnitedHealth Group Inc, reported by Conway Patrick Hugh (CEO, Optum).

Company-level read

Ticker impact

$UNHNeutralMedium confidence
Context

UNH CEO of Optum, Conway Patrick Hugh, filed a Form 4 open-market sale of 500 shares at $410 on 2026-08-05.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider sales can be routine and are not, by themselves, a new operating or guidance catalyst. The article provides transaction size, price, and post-sale holdings, but no accompanying company-specific news.

Market effects

Minimal; single-insider transaction in a large managed-care name does not change sector fundamentals.

None indicated.

None indicated.

Counterpoint

The sale may be tax or diversification related, especially since the filing does not provide context for motive and insider sales are often pre-planned even when not explicitly labeled as 10b5-1.

Key entities

  • UnitedHealth Group Inc

    Subject of the Form 4 insider transaction disclosure.

  • Conway Patrick Hugh

    Optum CEO and reporting insider who sold shares.

  • Optum

    Operating unit where the insider serves as CEO.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYMed

Florida Sues Eli Lilly, Novo Nordisk and Pharmacy Benefit

Florida sued Eli Lilly, Novo Nordisk, and pharmacy benefit managers, alleging they used rebates to maintain high drug prices, harming patients and independent pharmacies. The state claims these practices discouraged competition and limited access to affordable treatments, seeking damages and changes to pricing practices. The case focuses on insulin and GLP-1 medications, with Florida citing significant market power among the defendants.

$UNHMedAI 8/10

The One Cost Line UnitedHealth Stock Has Not Caught Up To Yet

UnitedHealth (UNH) reports Medicare costs below estimates for 2026, but commercial health plan costs are higher than expected. Management attributes commercial cost increases to the federal arbitration process under the No Surprises Act. UNH expects commercial margin recovery to extend past 2027, delaying full margin expansion. The company raised its 2026 adjusted EPS guidance to $19.50-$20 and maintains a 13%-16% long-term growth rate.

$UNHMed

Unitedhealth Group Inc (UNH) Stock News & Articles

UnitedHealth Group (UNH) shares fell 3% following TPG's acquisition of Florida WellMed Clinics, ahead of guidance reaffirmation. The deal involves Optum clinics that previously impacted UnitedHealth's profits. The company is set to reaffirm its guidance soon, which could validate the deal or raise concerns among investors.